Merck (MRK) ended the recent trading session at $111.01, demonstrating a +2.54% change from the preceding day's closing price ...

Merck's biggest cash cow could soon face competition from two drugs in development. However, the company is working on ways to get around this potential headwind. These are all good things, none of ...

On December 17, the US Food and Drug Administration moved to fast-track reviews of two experimental Merck & Co., Inc.

Merck KGaA’s healthcare biz arm EMD Serono announces US FDA accepted its NDA for pimicotinib to treat patients with TGCT: Boston Thursday, January 15, 2026, 12:00 Hrs [IST] EMD ...

Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut administrative, ...

Bayer AG’s proposed purchase of Merck & Co.’s consumer health unit would create a combined over-the-counter business with many of the products in a typical medicine chest. Sales in 2013 for the top ...

NIH, Merck and Gates MRI completes phase I trial of TBD09/MK-7762 TB drug candidate: Our Bureau, Bengaluru Wednesday, January 14, 2026, 14:45 Hrs [IST] Merck, known as MSD outside ...

Matthew Herper covers medical innovation — both its promise and its perils. Merck said a new formulation of the best-selling drug, Keytruda, appears to deliver similar blood levels of the medicine ...

While increasing collaboration between payers and providers was a major theme at HIMSS in Orlando last week, one other major stakeholder has been quite a bit harder to find in conversations about big ...

Merck (MRK) closed the most recent trading day at $110.99, moving +2.2% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.01%. Meanwhile, the Dow experienced a rise ...

PLEASANTON, Calif., July 12, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Merck KGaA, Darmstadt, Germany is using Veeva Vault MedInquiry as its global medical information ...